Akademik Veri Yönetim Sistemi
21st International Headache Congress, Seoul, Güney Kore, 14 - 17 Eylül 2023, cilt.43, ss.244-245, (Özet Bildiri)
Objective: This study aimed to investigate the efficacy,
effectiveness, and safety of Galcanezumab in treating
migraine in real-life setting, as well as identify predictors
of treatment response.
Methods: We recruited 461 patients with migraine (80.9%
females, 50.3% episodic form) in Turkey. Demographics,
clinical features of migraine and Galcanezumab treatment
experiences were recorded through a Google form after an
interview.
Results: The mean age was 42.8(10.6; range ¼ 18–77
years) and mean duration of migraine was 18.9(10.7)
years. In our cohort, 88.9% (n ¼ 410) reported that the
Galcanezumab treatment was beneficial for them. The
average time to benefit from the medication was 1.85
(2.2) months and average duration of treatment discontinuation was 6.6(3.8) months.
With Galcanezumab treatment, 71.2% of patients experienced a decrease in headache frequency, 68% reported a
decrease in headache severity, and 68.9% experienced a
decrease in analgesic use. The mean number of monthly
headache days (MHD) before treatment was 14.7(8.1),
while the number of MHD in the last month was reported
as 4.8(6.0).
Treatment discontinuation occurred in 128 patients, with
8.9% (n ¼ 41) discontinuing due to ineffectiveness,
244 Cephalalgia 43(1S)
! International Headache Society 2023
1.7% (n ¼ 8) discontinuing due to side effects, and the
majority (17.1%) discontinuing due to economic reasons.
Among these latter patients, 4.3% resumed treatment.
The most common side effects were constipation (5.2%)
and injection site reactions (3.9%).
The most bothersome symptoms during an attack were
reported as photophobia (38.2%) and nausea (23.0%). After
treatment, photophobia improved by 50–100% in 56.6%
(n¼ 261) of patients, and nausea improved in 62.7%
(n¼ 289). The rates of benefit from Galcanezumab were
reported as 50–74% in 125 of patients, 75–99% in 209
patients, and 100% in 64 (13.9%) of patients. 59.1%
reported improvement in their quality of life, and 35.4%
reported improvement in their sleep quality.
Conclusion: Male gender, previous history with sleep
disturbances, and ictal nausea were suggested as negative
predictors of treatment response to Galcanezumab in
patients with migraine in Turkey